The inhalation sedatives market consists of sales of inhalation sedatives by companies who manufacture them. Inhalation sedatives are the drugs used to induce or maintain inhalation sedation, which is a type of conscious sedation where a drug is inhaled to suppress the central nervous system activity so that there is no much stress on the patient during a surgical process or a treatment and responds to the physician commands without protective reflexes. Inhalation sedatives are used in hospitals, ambulatory surgical centers and other care providing centers.
The global inhalation sedatives market is expected to increase from $1.27 billion in 2019 to $1.29 billion in 2020 at a compound annual growth rate (CAGR) of 1.2%. The growth is mainly due to the COVID-19 outbreak. The infected individuals with severe ARDS require sedation most frequently, and inhalation sedatives are being increasingly considered as they are associated with rapid onset of inhalation and effective outcomes. Inhaled sedatives can reduce lung inflammation, shorten the duration of ventilation and potentially improve survival. The market is then expected to stabilize and reach $1.48 billion in 2023 at a CAGR of 4.8%.